Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average on Analyst Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares passed above its 50-day moving average during trading on Tuesday after Weiss Ratings upgraded the stock from a hold (c) rating to a hold (c+) rating. The stock has a 50-day moving average of $16.95 and traded as high as $17.10. Theravance Biopharma shares last traded at $17.06, with a volume of 251,659 shares.

Several other equities analysts also recently issued reports on the stock. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. HC Wainwright downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their price target for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Theravance Biopharma has a consensus rating of “Hold” and an average target price of $19.40.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. The trade was a 5.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the transaction, the insider directly owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Squarepoint Ops LLC acquired a new position in Theravance Biopharma in the second quarter valued at approximately $302,000. Groupe la Francaise purchased a new position in shares of Theravance Biopharma during the 2nd quarter worth $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Theravance Biopharma during the 2nd quarter worth about $1,071,000. California State Teachers Retirement System raised its holdings in Theravance Biopharma by 1,550.9% in the 2nd quarter. California State Teachers Retirement System now owns 672,911 shares of the biopharmaceutical company’s stock valued at $11,439,000 after buying an additional 632,150 shares during the period. Finally, GTS Securities LLC acquired a new position in Theravance Biopharma in the second quarter valued at about $430,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

The company has a market cap of $883.68 million, a PE ratio of 16.85 and a beta of 0.25. The company’s 50 day simple moving average is $16.95 and its two-hundred day simple moving average is $16.46.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The company had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. Sell-side analysts expect that Theravance Biopharma, Inc. will post 1.56 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.